Product Description: Ribociclib hydrochloride (LEE011 hydrochloride) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.
Applications: Cancer-Kinase/protease
Formula: C23H31ClN8O
Citations: bioRxiv. 2023 Sep 16./Clin Cancer Res. 2015 Nov 1;21(21):4947-59./JCI Insight. 2021 Dec 21;e154402./Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):4001-4011./Biomed Chromatogr. 2020 Mar;34(3):e4783./Biomed Pharmacother. 2019 Feb 18;112:108602. /Biomed Res Int. 2020 Jun 11;2020:9525207./bioRxiv. 2024 Nov 15:2024.11.11.623139./Breast Cancer Res. 2019 Dec 26;21(1):150./Cancer Cell. 2024 Aug 27:S1535-6108(24)00305-2./Cancer Discov. 2023 Dec 4./Cancer Res. 2019 Oct 15;79(20):5245-5259./Cancers (Basel). 2022, 14(22), 5481/Cancers. 2020 Jun 16;12(6):1596./Cell Chem Biol. 2019 Aug 15;26(8):1067-1080.e8. /Cell Death Dis. 2020 Sep 15;11(9):754./Cell Rep Med. 2023 Sep 12;101200./Cell Rep Methods. 2023 Oct 23;3(10):100599./Cell Rep. 2017 Oct 31;21(5):1386-1398./Cell Rep. 2020 Aug 4;32(5):107995./Cell. 2023 Jun 8;186(12):2628-2643.e21./Clin Cancer Res. 2015 Nov 1;21(21):4947-59./Clin Cancer Res. 2024 Dec 30./Department of Biochemistry. 2020 Oct./Eur J Cancer. 2018 Oct;102:10-22./Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11./Front Oncol. 2022 Apr 8;12:819003./Fundam Clin Pharmacol. 2021 Feb 1./Harvard Medical School LINCS LIBRARY/Int J Biol Sci. 2019 Jan 1;15(3):522-532. /J Chromatogr B. 2020 Jun 15;1147:122142./J Infect Dis. 2018 Nov 22;218(suppl_5):S365-S387./J Pharmaceut Biomed. 2021, 113933./J Transl Med. 2022 May 13;20(1):217./J Virol. 2023 May 23;e0037023./Leuk Res. September 2022, 106920./Mil Med Res. 2022 Dec 19;9(1):71./Mol Cancer Ther. 2018 May;17(5):897-907./Mol Cell. 2017 Oct 19;68(2):336-349.e6./Mol Oncol. 2017 Aug;11(8):1035-1049./Nat Commun. 2021 Sep 10;12(1):5386./Nat Commun. 2022 Aug 10;13(1):4689./Nat Commun. 2019 Jun 28;10(1):2860./Nature Cancer. 2021 Apr;2(4):429-443./Naunyn Schmiedebergs Arch Pharmacol. 2023 Feb 4./NPJ Precis Oncol. 2021 Mar 19;5(1):20./Patent. US20220354911A1./PLoS One. 2022 Dec 22;17(12):e0279522./PLoS One. 2024 August 28./Research Square Print. November 7th, 2022/RSC Adv. 2020, 10(38):22668-22683./Sci Adv. 2022 Dec 23;8(51):eadc8911./Sci Rep. 2021 Mar 8;11(1):5374./Sci Rep. 2022 Jul 20;12(1):12420./Sci Transl Med. 2018 Jul 18;10(450):eaaq1093./Texas Southern University. 2024 July 02./Transl Oncol. 2024 Aug 16:49:102092./Cell Chem Biol. 2018 Feb 15;25(2):135-142.e5./Nat Commun. 2021 Aug 25;12(1):5112.
References: [1]VanArsdale T, et al. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. Clin Cancer Res. 2015 Jul 1;21(13):2905-10./[2]Rader J, et al. Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
CAS Number: 1211443-80-9
Molecular Weight: 471.00
Compound Purity: 99.95
Research Area: Cancer
Solubility: DMSO : 7.69 mg/mL (ultrasonic)/H2O : 10 mg/mL (ultrasonic)
Target: CDK
English
Deutsch
